clinical trial · NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC·phase3·not yet recruiting·n = 700
Multiple MyelomaJNJ-79635322Teclistamab
brief summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.
started
Jun 8, 2026
primary completion
Apr 29, 2029
completion
Dec 8, 2032
last updated
Apr 13, 2026
official title
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol